Project Grant R01AI194820
- This $536,943.46 Project Grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases funds research at The Scripps Research Institute-Florida on identifying host factors that regulate HIV latency and reactivation. The grant supports three aims over a six-month period: defining the roles of proteins P32, FUBP3, and PHB2 in HIV transcription and chromatin structure; investigating protein complexes associated with P32, FUBP3, and PHB2 and their interaction...
- The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...
- This Project Grant award of $285,816 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research to enhance understanding of ADP-ribosylation (ADPR) and its role in HIV-1 latency and reactivation. The awardee, The Regents of the University of California, San Francisco, will conduct biochemical, proteomic, and cellular assays to identify global proteomic changes to ADPR during HIV-1 latency and reactivation,...
- This $624,902 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the impact of the HIV accessory protein Vpr on epigenetic remodeling and viral persistence in myeloid cells. The 5-year project, starting on Apr 23, 2025, will focus on characterizing how Vpr induces epigenetic changes to facilitate sustained HIV transcription and latency reactivation, as well as...
- This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the dynamics and evolution of HIV Gag and GagPol processing. The $752,745 award aims to use molecular dynamics simulations, single-molecule FRET imaging, and cryo-electron tomography to probe the structure and dynamics of Gag and GagPol that enable ordered processing by the viral...
- This Project Grant award of $486,057 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a multipronged mRNA gene therapy approach to address challenges in achieving an HIV cure. The award aims to develop three novel mRNA-based interventions: targeted delivery of the viral protein Tat to activate HIV transcription, hepatic delivery of mRNA encoding HIV-neutralizing...
- This Project Grant award of $800,389.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The proposed treatment combines soluble IL-15/IL-15RA-FC with a TGF-β pathway blockade and therapeutic vaccination to enhance and restore anti-viral immunity, leading to sustained viral remission...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $859,992 Project Grant to Yale University for the "Molecular Investigations of HIV-1 Maturation Pathways and Inhibitor Actions in situ" research project. The grant, funded under NIAID's Allergy and Infectious Diseases Research Program (CFDA 93.855), aims to use advanced in-situ cryo-electron microscopy and tomography techniques to visualize the structural transitions of the HIV-1 virus during the maturation...
- This $197,366 Project Grant was awarded on March 1, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to identify the molecular mechanisms that control the natural, immune-mediated restriction of X4-tropic HIV virus, which typically emerges only in late-stage HIV disease when the immune system is impaired. The research will utilize primary CD4 T cells, in vivo analyses in...
- This $118,488 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) on January 20, 2025, supports research to develop HIV-resistant hematopoietic stem cells through targeted base editing. The project aims to identify genetic mutations in the CCR5 and CXCR4 co-receptors that can prevent HIV entry into CD4 cells while maintaining the central functions of these proteins in hematopoiesis. The research involves...
This Project Grant award of $1,016,887.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is for research to discover novel inhibitors of the HIV-1 Tat protein, which plays a critical role in regulating viral latency and reactivation. The research aims to identify structurally distinct Tat inhibitor candidates with more cost-effective synthesis compared to existing inhibitors like didehydro-cortistatin A. This work supports the "block-and-lock" HIV functional cure strategy, which uses transcriptional inhibitors to promote epigenetic silencing of proviral expression and prevent viral reactivation upon treatment interruption. The project will be conducted at the University of Florida from August 6, 2025 to July 31, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.0m | 8/6/25 |